Syndax Pharmaceuticals (SNDX) EBITDA (2016 - 2020)
Historic EBITDA for Syndax Pharmaceuticals (SNDX) over the last 6 years, with Q4 2020 value amounting to -$19.9 million.
- Syndax Pharmaceuticals' EBITDA fell 3980.99% to -$19.9 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$71.4 million, marking a year-over-year decrease of 2412.97%. This contributed to the annual value of -$339.7 million for FY2024, which is 4771.3% down from last year.
- As of Q4 2020, Syndax Pharmaceuticals' EBITDA stood at -$19.9 million, which was down 3980.99% from -$19.9 million recorded in Q3 2020.
- Syndax Pharmaceuticals' 5-year EBITDA high stood at -$8.4 million for Q2 2016, and its period low was -$19.9 million during Q4 2020.
- For the 5-year period, Syndax Pharmaceuticals' EBITDA averaged around -$15.5 million, with its median value being -$15.1 million (2017).
- Its EBITDA has fluctuated over the past 5 years, first tumbled by 15710.14% in 2016, then soared by 2652.46% in 2019.
- Over the past 5 years, Syndax Pharmaceuticals' EBITDA (Quarter) stood at -$11.1 million in 2016, then crashed by 74.93% to -$19.5 million in 2017, then rose by 0.8% to -$19.3 million in 2018, then rose by 26.52% to -$14.2 million in 2019, then crashed by 39.81% to -$19.9 million in 2020.
- Its last three reported values are -$19.9 million in Q4 2020, -$19.9 million for Q3 2020, and -$16.6 million during Q2 2020.